BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24386456)

  • 1. Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian cancer xenograft tumors in mice using FDG and FLT PET.
    Munk Jensen M; Erichsen KD; Björkling F; Madsen J; Jensen PB; Sehested M; Højgaard L; Kjær A
    PLoS One; 2013; 8(12):e85126. PubMed ID: 24386456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts.
    Jensen MM; Erichsen KD; Johnbeck CB; Björkling F; Madsen J; Bzorek M; Jensen PB; Højgaard L; Sehested M; Kjær A
    PLoS One; 2013; 8(1):e53410. PubMed ID: 23308217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice.
    Jensen MM; Erichsen KD; Björkling F; Madsen J; Jensen PB; Højgaard L; Sehested M; Kjær A
    PLoS One; 2010 Sep; 5(9):e12965. PubMed ID: 20885974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.
    Jensen MM; Erichsen KD; Johnbeck CB; Björkling F; Madsen J; Jensen PB; Sehested M; Højgaard L; Kjær A
    BMC Cancer; 2013 Apr; 13():168. PubMed ID: 23548101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice.
    Munk Jensen M; Erichsen KD; Björkling F; Madsen J; Jensen PB; Sehested M; Højgaard L; Kjær A
    PLoS One; 2012; 7(11):e50618. PubMed ID: 23226334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
    Nielsen CH; Jensen MM; Kristensen LK; Dahlman A; Fröhlich C; Jacobsen HJ; Poulsen TT; Lantto J; Horak ID; Kragh M; Kjaer A
    Oncotarget; 2015 Nov; 6(35):37486-99. PubMed ID: 26460961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
    Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
    Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose- and 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer.
    Perumal M; Stronach EA; Gabra H; Aboagye EO
    Mol Imaging Biol; 2012 Dec; 14(6):753-61. PubMed ID: 22484552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
    Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
    J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.
    Geven EJ; Evers S; Nayak TK; Bergström M; Su F; Gerrits D; Franssen GM; Boerman OC
    Contrast Media Mol Imaging; 2015; 10(3):203-10. PubMed ID: 25204436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
    Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
    Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy.
    Martoni AA; Fanti S; Zamagni C; Rosati M; De Iaco P; D'Errico Grigioni A; Castellucci P; Quercia S; Musto A; Ricci Maccarini L; Lopci E; Bernardi A
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):81-90. PubMed ID: 21068714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
    de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging proliferation in human leukemia-tumor bearing mice with (18)F-FLT: Comparison with (18)F-FDG PET.
    Lu L; Jiang L; Guan H; Gao Y; Lu H
    Hell J Nucl Med; 2012; 15(3):206-9. PubMed ID: 23106052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using dual-tracer PET to predict the biologic behavior of human colorectal cancer.
    Wang H; Zhang J; Tian J; Qu B; Li T; Chen Y; Liu J; Wang S
    J Nucl Med; 2009 Nov; 50(11):1857-64. PubMed ID: 19837754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
    Cullinane C; Dorow DS; Jackson S; Solomon B; Bogatyreva E; Binns D; Young R; Arango ME; Christensen JG; McArthur GA; Hicks RJ
    J Nucl Med; 2011 Aug; 52(8):1261-7. PubMed ID: 21764800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG and 18F-FLT-PET imaging for monitoring everolimus effect on tumor-growth in neuroendocrine tumors: studies in human tumor xenografts in mice.
    Johnbeck CB; Munk Jensen M; Haagen Nielsen C; Fisker Hag AM; Knigge U; Kjaer A
    PLoS One; 2014; 9(3):e91387. PubMed ID: 24626055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer.
    Ott K; Herrmann K; Schuster T; Langer R; Becker K; Wieder HA; Wester HJ; Siewert JR; zum Büschenfelde CM; Buck AK; Wilhelm D; Ebert MP; Peschel C; Schwaiger M; Lordick F; Krause BJ
    Ann Surg Oncol; 2011 Nov; 18(12):3316-23. PubMed ID: 21537865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic 2-Deoxy-2-[
    Kristian A; Holtedahl JE; Torheim T; Futsaether C; Hernes E; Engebraaten O; Mælandsmo GM; Malinen E
    Mol Imaging Biol; 2017 Apr; 19(2):271-279. PubMed ID: 27541026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by (18)F-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Leimgruber A; Möller A; Everitt SJ; Chabrot M; Ball DL; Solomon B; MacManus M; Hicks RJ
    J Nucl Med; 2014 Jul; 55(7):1075-80. PubMed ID: 24868108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.